UBS Maintains Buy on Abbott Laboratories, Lowers Price Target to $125

Benzinga Newsdesk www.benzinga.com Negative 46.4%

Neg 46.4% Neu 0% Pos 0%

UBS analyst Patrick Wood maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $125.